Search

Search Constraints

You searched for: Author/Creator Oster, Wolfgang

Search Results

1. ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS. (5th November 2018)

2. ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. (5th November 2018)

3. ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. (11th November 2019)

4. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Issue 1 (8th November 2019)

5. DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY. (5th November 2018)

6. DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. (5th November 2018)

7. DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY. (11th November 2019)

8. DIPG-42. CAN WE CHANGE THE LANDSCAPE OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)? FIRST DEMONSTRATION OF CLINICAL AND RADIOGRAPHIC RESPONSE IN A PEDIATRIC H3-K27M MUTATED DIPG TO THE DRD2-ANTAGONIST ONC201. Issue 2 (22nd June 2018)

9. DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG. (4th December 2020)